Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma.

Rujkijyanont P, Chan WK, Eldridge PW, Lockey T, Holladay M, Rooney B, Davidoff AM, Leung W, Vong Q.

Cancer Res. 2013 Apr 15;73(8):2608-18. doi: 10.1158/0008-5472.CAN-12-3322. Epub 2013 Feb 25.

2.

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC.

Clin Cancer Res. 2013 Apr 15;19(8):2132-43. doi: 10.1158/1078-0432.CCR-12-1243. Epub 2013 Feb 1.

3.

A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.

Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B, Dilber MS.

Hum Immunol. 2001 Oct;62(10):1092-8.

PMID:
11600215
4.

GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, Min B, Shin H, Kim TM, Heo DS, Hwang YK, Shin EC.

PLoS One. 2013;8(1):e53611. doi: 10.1371/journal.pone.0053611. Epub 2013 Jan 11.

6.

Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood.

Condiotti R, Zakai YB, Barak V, Nagler A.

Exp Hematol. 2001 Jan;29(1):104-13.

PMID:
11164111
7.

Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.

Alves PC, Andrade LA, Petta CA, Lorand-Metze I, Derchain SF, GuimarĂ£es F.

Scand J Immunol. 2011 Sep;74(3):244-52. doi: 10.1111/j.1365-3083.2011.02576.x.

8.

Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.

Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I.

Immunology. 2001 Jul;103(3):281-90.

9.

Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.

Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KM.

Cancer Res. 2013 Apr 15;73(8):2598-607. doi: 10.1158/0008-5472.CAN-12-2893. Epub 2013 Apr 11.

10.

Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.

Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, Bilban M, Schlechta B, Dolstra H, Hofer E.

Stem Cells Dev. 2012 Nov 1;21(16):2926-38. doi: 10.1089/scd.2011.0659. Epub 2012 Jul 17.

11.

Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells.

Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, Santos F, Henriques A, GrĂ£os M, Cardoso CM, Martinho A, Pais M, da Silva CL, Cabral J, Trindade H, Paiva A.

Stem Cell Res Ther. 2013 Oct 15;4(5):125. doi: 10.1186/scrt336.

12.

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.

Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M.

Blood. 2011 Sep 22;118(12):3301-10. doi: 10.1182/blood-2011-02-336321. Epub 2011 Aug 5.

13.

IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.

Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U.

J Immunother. 2010 Feb-Mar;33(2):200-10. doi: 10.1097/CJI.0b013e3181bb46f7.

PMID:
20145545
14.

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ.

PLoS One. 2013 Oct 18;8(10):e76781. doi: 10.1371/journal.pone.0076781. eCollection 2013.

16.

Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.

Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C, Moretta A.

Cancer Res. 2004 Dec 15;64(24):9180-4.

17.

[Selective expansion of human natural killer cells].

Peng BG, Liang LJ, He Q, Li J, Lu MD.

Ai Zheng. 2005 Oct;24(10):1287-9. Chinese.

PMID:
16219151
18.

IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells.

Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M.

Cancer Res. 2010 Dec 1;70(23):9611-20. doi: 10.1158/0008-5472.CAN-10-1968. Epub 2010 Oct 14.

19.

The IL-12 signature: NK cell terminal CD56+high stage and effector functions.

Loza MJ, Perussia B.

J Immunol. 2004 Jan 1;172(1):88-96.

20.
Items per page

Supplemental Content

Write to the Help Desk